Implantable Sensor Enters First Clinical Trial

Senseonics Holdings announces that the extended life Eversense XL sensor that lasts up to 180 days has been implanted in the first US study participant as part of the clinical trial for pre-market application submission to the Food and Drug Administration. The study is intended to evaluate the safety and efficacy of the Eversense CGM system in people with diabetes over a 180-day period.

 

Approximately 180 study participants at up to 15 locations across the United States are planned to enroll in the study. The Eversense XL sensor previously received the CE Mark and is currently marketed to patients across the European Union.

SENSORS EXPO & CONFERENCE

Sensors 2019 Hits Silicon Valley June 25-27!

Join 7,000+ engineers this June in San Jose at the sensor industry’s biggest event! With 65+ Technical Sessions, 100+ Leading Speakers, 10 new and updated tracks, and 300+ Interactive Exhibits, there’s more opportunity than ever to connect with this booming industry and the technologies driving it. See thousands of the newest technologies in action, learn about the latest applications, and develop invaluable partnerships at the only event dedicated to sensors, connectivity, and systems.

 

Senseonics also announced that the company has completed its submission of PMA supplements to the FDA to secure an insulin dosing claim and to remove the contraindication related to the Magnetic Resonance Imaging (MRI) exposure on the 90-day system which is currently available in the United States.

 

For more information, visit Senseonics.

Read more on

Suggested Articles

Solar product achieves stellar efficiency levels.

Flowmeter measures and monitors small to medium sized flow of conductive liquids.

100% solid-state polymer electrolytic membranes offer advantages over standard liquid electrolytes.